Since cancer patients who express low levels of HtrA1 have poorer responses to a few chemotherapy drugs, it is suggested that HtrA1 may serve as a potentially useful biomarker in selecting chemotherapy treatments [99]. The gene discussed is HTRA1; the disease is cancer.